Pregnancy considerations: Tirzepatide is not recommended during pregnancy, and women of childbearing potential should be advised that tirzepatide may reduce the effectiveness of oral contraceptives, particularly during initiation and dose escalation
How tirzepatide works Tirzepatide, also known by the brand names Mounjaro and Zepbound, is an FDA-approved dual-action GLP-1/GIP receptor agonist made by Eli Lilly
The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and is not indicated for type 1 diabetes or use with other GLP-1 receptor agonists
Semaglutide and tirzepatide are "upstream" they act on incretin receptors to influence appetite regulation, gastric emptying, and glucose-dependent insulin secretion
(The FDA has received more than 700 adverse event reports tied to compounded GLP-1s, but its not clear if the events were caused by the drugs.) The companies also see compounders as a threat to their obesity drug sales, which are estimated to balloon to $100 billion a year by 2030
Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription GLP-1 medication used for weight loss and weight management, type 2 diabetes treatment, or to reduce the risk of chronic kidney disease and major cardiovascular events in certain patients with type 2 diabetes
